| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/23/2026 | ±2.4% | +1.4% | over-priced |
| 04/22/2026 | ±2.3% | -0.0% | over-priced |
| 10/22/2025 | ±1.4% | +0.6% | over-priced |
| 07/24/2025 | ±1.5% | +0.3% | over-priced |
| 04/23/2025 | ±2.3% | -1.5% | over-priced |
| 10/23/2024 | ±1.2% | +1.5% | under-priced |
| 07/25/2024 | ±1.7% | +2.1% | under-priced |
| 05/01/2024 | ±1.5% | +4.6% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2027 | $2.27 | $25.3B | $5.5B |
| Q4 FY2026 | $2.14 | $24.1B | $5.2B |
| Q4 FY2025 | $2.09 | $24.6B | $5.1B |
| Q3 FY2025 | $2.12 | $24.0B | $5.2B |
Johnson & Johnson (JNJ) reports in 64 days, with the next report estimated for 11/14/2026. Across the last 8 reports, options priced an average ±1.8% earnings move while the stock actually moved 1.5% on average — the market has been roughly fair on JNJ's earnings risk. Fundamentals into the print: EPS down 0.9% year-over-year, revenue up 6.6%. QuantLogix's live 5-factor engine currently reads JNJ as a buy at 59/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →